MIR4 Releases Updates With Exciting New Battle Content
5.10.2021 08:00:00 EEST | Business Wire | Press release
Wemade Co., Ltd.’s masterpiece mobile MMORPG, MIR4 released new battle content, 'Attack of the Living Wraiths', on October 5. Attack of the Living Wraiths will be held every Thursday from 10:00 to 11:00 pm local server time, throughout the fourth floor in Bicheon, Snake, and Redmoon Hidden Valleys.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004006051/en/
Wemade Co., Ltd.’s masterpiece mobile MMORPG, MIR4 released new battle content, 'Attack of the Living Wraiths'. Once Attack of the Living Wraiths begin, players will be able to fight fiercely against named monsters, semi-bosses, and boss monsters, while acquiring treasure chests. Attack of the Living Wraiths will be held every Thursday from 10:00 to 11:00 pm local server time, throughout the fourth floor in Bicheon, Snake, and Redmoon Hidden Valleys. In addition, a new Raid (Wailing Dead Mine - level 115) as well as a new Boss Raid (Nefariox King - level 105) is included with the update. Future update plans include Class Change and release of a new character - Arbalist, expected to be released in November. (Graphic: Business Wire)
"Once Attack of the Living Wraiths begin, players will be able to fight fiercely against named monsters, semi-bosses, and boss monsters, while acquiring treasure chests with rich rewards such as Epic-grade Dragon Materials, Mystic Enhancement Stones, and Blue Dragon statues,” says Wemade. "Those who defeat named monsters will have a chance to summon semi-boss monsters, and by overcoming semi-boss monsters, a boss monster may appear by chance."
In addition to Attack of the Living Wraiths content, a new Raid (Wailing Dead Mine - level 115) as well as a new Boss Raid (Nefariox King - level 105) is included with the update. Players who defeat [Nefariox King: Boss Raid] will become eligible to purchase a new mount - 'Hell Horse'.
Future update plans include Class Change and release of a new character - Arbalist, expected to be released in November. Class change, unlocked when the character reaches level 50, allows players to switch characters between: Warrior, Sorcerer, Taoist, Lancer, and Arbalist, while maintaining the character’s physical constitution, inner strength, and solitude training. Arbalist, the only long-distance physical attack type character in MIR4, has extreme destructive power through the use of improved-crossbow and possesses excellent survivability through martial arts prowess.
From my battle to our war! Visit the official website for more information about MIR4.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004006051/en/
Contact information
Press contact:
Wemade Co., Ltd. (112040: KOSDAQ)
Yeonghyun Lee, PR Manager
yeonghyun@wemade.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom